Intro

This chapter explores the promising role of GLP-1 medications, such as Ozempic and Wigovi, in mitigating cravings linked to addiction. It features expert insights on the broader implications of these drugs beyond weight loss, advocating for a more flexible regulatory framework to aid those battling substance use disorders.